PORTA SOPRANA – FRIDAY 6 SEPTEMBER

17.30

Recombinant, patient-derived FVIII-neutralising antibodies: a platform for research, product testing, and ex vivo modelling of haemophilia A
C. Coxon (UK)
VIEW ePOSTER

17.40

Use of chromogenic Factor VIII activity determination in Haemophilia A plasma of patients under emicizumab treatment
N. Binder (Austria)
VIEW ePOSTER

17.50

Performance evaluation of a new fully automated thrombin generation instrument for the measurement of TGA in Haemophilia samples
N. Binder (Austria)
VIEW ePOSTER

18.00

ADAMTS13 Inhibitor Assessment with the HemosIL AcuStar ADAMTS13 Activity Assay
C. Valsecchi (Italy)
VIEW ePOSTER

18.10

Exploration and treatment strategies for gastrointestinal bleeding in Von Willebrand Disease over a 3-year period: a french-nationwide retrospective survey
A. Rauch (France)
VIEW ePOSTER

PORTA SOPRANA – SATURDAY 7 SEPTEMBER

18.30

Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency
J.L. Saes (The Netherlands)
VIEW ePOSTER

18.40

Quantification of VWF propeptide release before and after desmopressin in von Willebrand disease and hemophilia A
L. Bukkems (The Netherlands)
VIEW ePOSTER

18.50

In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effect
C. Casari (Italy)
VIEW ePOSTER

19.00

Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura
I. Mancini (Italy)
VIEW ePOSTER

19.10

Non-specific non-antiphospholipid inhibitor in a 26-years-old woman: a case report with few answers and many questions
N. Ciavarella (Italy)
VIEW ePOSTER